Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Wiskott-Aldrich Syndrome
NCT00909363Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Jun 2009
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eltrombopag in Wiskott-Aldrich syndrome (WAS), X-linked thrombocytopenia (XLT), sponsored by Weill Cornell Medicine. Started Jun 2009; status: terminated.
02
Drugs
eltrombopag
03
Conditions
Wiskott-Aldrich syndrome (WAS)X-linked thrombocytopenia (XLT)
Beyond the preview
Go deeper on NCT00909363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00909363.